Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
about
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritisMechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications.Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblastsManagement of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture.Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse.Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral skeleton.Stemming bone loss by suppressing apoptosis.Metabolic bone disease in adults with inflammatory bowel disease.Proteomics in bone research.Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormoneIntermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.Reduced fracture risk with early corticosteroid withdrawal after kidney transplant.Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.Osteoporosis in systemic lupus erythematosus: prevention and treatment.Role of teriparatide in treatment of glucocorticoid-induced osteoporosis2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.Parathyroid hormone for the treatment of osteoporosis: a systematic review.Osteoporosis in the rheumatic disease patient.Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.Novel treatments for osteoporosis.Prevention of glucocorticoid induced bone changes with beta-ecdysone.Glucocorticoid dose determines osteocyte cell fate.Medical treatment of vertebral osteoporosisSteroids cause osteoporosis.How to prevent steroid induced osteoporosis.Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.Disorders associated with acute rapid and severe bone loss.Teriparatide for severe osteoporosis.Treatment of osteoporosis in men.Risk factors for osteoporosis in female patients with systemic lupus erythematosus.Local and systemic control of the osteoblast.Molecular and cellular mechanisms of the anabolic effect of intermittent PTHUtilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisTreatment of glucocorticoid-induced osteoporsisGlucocorticoid-induced osteoporosis: treatment update and review.Pulsatile release of parathyroid hormone from an implantable delivery system.Parathyroid hormone (1-84) and treatment of osteoporosis.Effectiveness of Teriparatide on Fracture Healing: A Systematic Review and Meta-Analysis.
P2860
Q24805600-6F376028-D1E5-49FD-8D5C-77086F35CAF3Q24806684-9880F1B6-D6AE-45A6-B5A1-C45152CFC34BQ28573174-8D1AEB87-E48E-47A1-A81C-31E135C06628Q30946308-B437C029-B8BE-4EBC-8A5B-CAFF0238C377Q31032314-240C4434-3879-4272-A338-8DE365299BCDQ33320934-88448DDE-14A3-4821-8688-67C03914F0C7Q33660658-4CE59BEA-A59A-431C-846A-AFEB41581D73Q33712675-7BB9D75E-79A4-410B-BA91-ED23EE2D9106Q33715517-7AC1D619-5D5F-4CB4-9C50-99416E8443DDQ33767411-4E016F9E-9476-405C-91C1-C5848C18E867Q33857424-46B3B5C2-2C69-4BA1-A2A3-05042F4FF009Q33874504-1D8BF1E3-7D68-4B22-A460-2616F73E158AQ34069674-2FDDCA7A-D919-47D9-AA30-0C99F9FE03A0Q34142098-D16676FD-3B02-4CBC-8DA8-0E27E4E37FE5Q34227091-D9CB2BED-B022-402D-8AD4-22A11478D58BQ34235921-8BA78656-7076-4711-A268-C389AC795064Q34300668-623AF134-B7FD-4630-AB07-995A66301A79Q34433399-D67E374A-6A4E-4183-BCCE-C2A4554D6754Q34695988-75B78DD3-FD1D-442A-A720-51AD360D9A75Q34986976-912AB47C-DD61-46CC-97B8-217CA30DCF9FQ35026459-C51D228C-67DE-4AC2-9FF9-E96DDC1683E3Q35126745-42F84482-903C-43C6-8E55-CBFE4535DC28Q35163490-53F63EA8-9FE4-4A00-AAF0-259DFF10E346Q35225093-DFF39DF4-8F9D-481B-85B5-154CF3F4F0B2Q35299212-75073BB8-5419-4C86-9B07-BC2A8D6C4F1BQ35550904-FE373C11-0DAA-4798-9920-6530429161CDQ35555248-432397D4-28DD-4FDC-ADC7-E1ACFDA31082Q35601856-F95C416D-0CC5-4AAE-A564-AB8087EAC0C6Q35606552-60EA30AC-7BD6-48DC-A941-DE70436A04CEQ35637987-4D894366-16F8-4AFA-9F16-0E98CB79D74AQ35895418-2380ACE5-49CE-4EC8-84F5-3D2370D9468DQ35918391-4A82B62B-C087-43DD-B30F-E9CD7774C2CBQ36010759-E37185CC-5CCE-4ED7-9F9F-A2E3E57C5F84Q36016775-94883BFF-8566-4FC5-AFDF-28AF485DCE00Q36045845-3D9227ED-2BF4-4DDE-95F3-2095431F8216Q36056932-CF74379A-7F6C-4AA6-A6C7-B058B59FB770Q36059394-3F4E5A0A-6A44-4EBF-A714-CF94E199570AQ36102547-C0702F69-2990-43A4-B512-4DCDFB980E19Q36217215-C935A24E-F8C4-4330-AF9F-EC58658C8469Q36229660-0C7DDAEC-58D8-41AC-924F-E584F4A6DD3F
P2860
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parathyroid hormone treatment ...... zed controlled clinical trial.
@en
Parathyroid hormone treatment ...... zed controlled clinical trial.
@nl
type
label
Parathyroid hormone treatment ...... zed controlled clinical trial.
@en
Parathyroid hormone treatment ...... zed controlled clinical trial.
@nl
prefLabel
Parathyroid hormone treatment ...... zed controlled clinical trial.
@en
Parathyroid hormone treatment ...... zed controlled clinical trial.
@nl
P2093
P2860
P356
P1476
Parathyroid hormone treatment ...... zed controlled clinical trial.
@en
P2093
P2860
P304
P356
10.1172/JCI3914
P407
P577
1998-10-01T00:00:00Z